BioSpace News Archive

PolarityTE, Inc. today announced the appointment of Chris Nolet to the Company’s Board of Directors and Chair of the Audit Committee. Mr. Nolet brings extensive audit and business experience with nearly forty years in the profession, most recently as the West Region Life Sciences Industry Leader and Partner

Donations complement Pfizer’s COVID-19 R&D investments, as well as collective scientific and philanthropic contributions made by the biopharmaceutical industry

European Commission Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment for ALK+ NSCLC

Hope Biosciences, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COV

Endologix, Inc. today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately $28.5 million.

Avita Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced preliminary estimates of its top line results for the three months ended 31 March 2020, together with an operating update relating to the COVID-19 pandemic.

TRACON Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted TRACON a Type B Teleconference to take place on May 8, 2020

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company’s website: www.medivir.com . The development in 2019 shows that the reorganization and refocus that was initiated at the end of 2018 was right for Medivir. Today we are an agile and efficient development company wit

CAE announced today that it has taken a series of flexible measures to protect its financial position in response to the COVID-19 crisis and mitigate the impact on its employees.

Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company’s operational and clinical activities.